- Home
- CHI vs CRMD Comparison
CHI vs CRMD Comparison
Compare CHI & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHI
- CRMD
- Stock Information
- Founded
- CHI 2002
- CRMD 2006
- Country
- CHI United States
- CRMD United States
- Employees
- CHI N/A
- CRMD N/A
- Industry
- CHI Investment Managers
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- CHI Finance
- CRMD Health Care
- Exchange
- CHI Nasdaq
- CRMD Nasdaq
- Market Cap
- CHI 762.2M
- CRMD 645.0M
- IPO Year
- CHI N/A
- CRMD 2010
- Fundamental
- Price
- CHI $9.59
- CRMD $6.16
- Analyst Decision
- CHI
- CRMD Strong Buy
- Analyst Count
- CHI 0
- CRMD 7
- Target Price
- CHI N/A
- CRMD $15.14
- AVG Volume (30 Days)
- CHI 186.2K
- CRMD 2.0M
- Earning Date
- CHI 01-01-0001
- CRMD 03-25-2025
- Dividend Yield
- CHI 9.90%
- CRMD N/A
- EPS Growth
- CHI N/A
- CRMD N/A
- EPS
- CHI N/A
- CRMD N/A
- Revenue
- CHI N/A
- CRMD $43,472,170.00
- Revenue This Year
- CHI N/A
- CRMD $204.98
- Revenue Next Year
- CHI N/A
- CRMD $22.54
- P/E Ratio
- CHI N/A
- CRMD N/A
- Revenue Growth
- CHI N/A
- CRMD N/A
- 52 Week Low
- CHI $9.70
- CRMD $3.61
- 52 Week High
- CHI $11.61
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- CHI 27.04
- CRMD 22.98
- Support Level
- CHI $9.97
- CRMD $6.92
- Resistance Level
- CHI $10.24
- CRMD $11.32
- Average True Range (ATR)
- CHI 0.17
- CRMD 0.68
- MACD
- CHI 0.00
- CRMD -0.49
- Stochastic Oscillator
- CHI 16.67
- CRMD 1.15
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.